Table 2 |
||||
|
Overview of included trials |
||||
|
Study, year (reference) |
Comparisons (initial drug-dosages) |
Sample size (total, included in analysis) |
Age group (years) |
Follow-up (mean, years) |
|
|
||||
|
VA II 1970 [43] |
Hydrochlorothiazide (50 mg/day) + reserpine (0.1 mg/day) + hydralazine hydrochloride (25 mg/day) vs. placebo |
380 |
30 to 73 |
3.3 |
|
|
||||
|
Oslo hypertension study 1980 [27] |
Hydrochlorothiazide (50 mg/day) vs. no treatment |
785 |
40 to 49 |
5.5 |
|
|
||||
|
EWPHE 1985 [44] |
Hydrochlorothiazide (25 mg/day) + triamteren (50 mg/day) vs. placebo |
840 |
> 60 |
4.7 |
|
|
||||
|
Coope 1986 [45] |
Atenolol (100 mg/day) or bendrofluazide (5 mg/day) vs. no treatment |
884 |
60 to 79 |
4.4 |
|
|
||||
|
HAPPHY 1987 [28] |
Bendroflumethiazide (5 mg/day) or hydrochlorothiazide (50 mg/day) vs. atenolol (100 mg/day) or metoprolol 200 mg/day) |
6,569 |
40 to 64 |
3.8 |
|
|
||||
|
STOP 1 1991 [46] |
Atenolol (50 mg/day) or HCTZ (25 mg/day) (add-on drugs: amiloride (2.5 mg/day) or metoprolol (100 mg/day) or pindolol (5 mg/day)) vs. placebo |
1,627 |
70 to 84 |
2 |
|
|
||||
|
SHEP 1991 [26] |
Chlortalidone (12.5 mg/day) vs. placebo |
4,736 |
> 60 |
4.5 |
|
|
||||
|
MRC 2 1992 [29] |
Hydrochlorothiazide+amiloride (25 + 2.5 mg/day) vs. atenolol (50 mg/day) vs. placebo |
4,396 |
65 to 74 |
5.8 |
|
|
||||
|
SYST-EUR 1997 [47] |
Nitrendipine (10 mg/day) vs. placebo |
4,695 |
> 60 |
4 |
|
|
||||
|
Sun 1997 [25] |
Nitrendipine (10 mg/day) (starting dose: 10 mg × 3, reduced to 10 mg × 1) vs. usual care |
2,080 |
> 15 |
4.7 |
|
|
||||
|
CAPPP 1999 [30] |
Captopril (50 mg/day) vs. atenolol (50 to 100 mg/day) or metoprolol (50 to 100 mg/day) or hydrochlorothiazide (25 mg/day) or bendroflumethiazide (2.5 mg/day) |
10,985 |
25 to 66 |
6.1 |
|
|
||||
|
NICS-EH 1999 [31] |
Nicardipine (20 mg × 2/day) vs. Trichlormethiazide (2 mg/day) |
414 |
≥ 60 |
4.6 (nicardipine group) and 3.9 (trichlormethia-zide group) |
|
|
||||
|
STOP-2 1999 [32] |
Atenolol (50 mg/day) or metoprolol (100 mg/day) or pindolol (5 mg/day) or hydrochlorothiazide (25 mg/day)+amilorid (2.5 mg/day) vs. enalapril (10 mg/day) or lisinopril (10 mg/day) vs. felodipine (2.5 mg/day) or isradipine (2.5 mg/day) |
6,614 |
70 to 84 |
4 to 6 |
|
|
||||
|
Doxazosine (2 mg/day) vs. chlorthalidone (12.5 mg/day) vs. amlodipine (2.5 mg/day) vs. lisinopril (10 mg/day) |
42,424 |
> 55 |
4.9 for chlorthalidone vs. amlodipine vs. lisinopril. 3.3 (median) for chlorthalidone vs. doxazosine |
|
|
|
||||
|
NORDIL 2000 [34] |
Diltiazem (180 to 360 mg/day) vs. thiazide (not specified) or beta-blocker (not specified) |
10,881 |
50 to 74 |
4.5 |
|
|
||||
|
INSIGHT 2000 [35] |
Nifedipine (30 mg/day) vs. hydrochlorothiazide (25 mg/day)+amilorid (2.5 mg/day) |
6,321 |
55 to 80 |
~3.5 |
|
|
||||
|
LIFE 2002 [36] |
Losartan (50 mg/day) vs. atenolol (50 mg/day) |
9,193 |
55 to 80 |
4.8 |
|
|
||||
|
ANBP 2 2003 [37] |
ACE-inhibitor (unspecified type and dosage) vs. thiazide-diuretic (unspecified type and dosage) |
6,083 |
65 to 84 |
4.1 |
|
|
||||
|
CONVINCE 2003 [38] |
Verapamil (180 mg/day) vs. atenolol (50 mg/day) or hydrochlorothiazide (12.5 mg/day) |
16,602 |
> 55 |
3 |
|
|
||||
|
HYVET-PILOT 2003 [39] |
Lisinopril (2.5 mg/day) vs. bendroflumethiazide (2.5 mg/day) vs. no treatment |
857 |
> 80 |
1.1 |
|
|
||||
|
SHELL 2003 [40] |
Chlorthalidone (12.5 mg/day) vs. lacidipine (4 mg/day) |
1,882 |
> 60 |
2.7 (median) |
|
|
||||
|
VALUE 2004 [49] |
Valsartan (80 mg/day) vs. amlodipine (5 mg/day) |
15,245 |
> 50 |
4.2 |
|
|
||||
|
E-COST 2005 [41] |
Candesartan (4 or 8 mg/day) vs. "conventional based regimen" |
1,630 |
35 to 79 |
3.1 |
|
|
||||
|
CASE-J 2008 [42] |
Candesartan (8 mg/day) vs. amlodipine (5 mg/day) |
4,703 |
63.8 (mean) |
3.2 |
|
|
||||
|
HYVET 2008 [48] |
Indapamid (1.5 mg/day) vs. placebo |
3,845 |
≥ 80 |
2.1 |
|
|
||||
|
Fretheim et al. BMC Medicine 2012 10:33 doi:10.1186/1741-7015-10-33 |
||||
